Cobus Loots, CEO of Pan African Resources, on delivering sector-leading returns for shareholders. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Regulatory News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,320.00
Bid: 12,318.00
Ask: 12,322.00
Change: -44.00 (-0.36%)
Spread: 4.00 (0.032%)
Open: 12,358.00
High: 12,358.00
Low: 12,294.00
Prev. Close: 12,364.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Result of AGM

29 Apr 2016 17:30

RNS Number : 9044W
AstraZeneca PLC
29 April 2016
 

ASTRAZENECA PLC - ANNUAL GENERAL MEETING 2016

 

Results of Annual General Meeting held on 29 April 2016

 

AstraZeneca PLC announced the results of the voting at its Annual General Meeting today. As proposed in the Notice of AGM, all Resolutions were decided by poll vote. Resolutions 1 - 8 were passed as ordinary resolutions and resolutions 9 - 11 were passed as special resolutions.

 

 

RESOLUTION

VOTES FOR

% OF VOTES CAST

VOTES AGAINST

% OF VOTES CAST

VOTES CAST IN TOTAL

TOTAL VOTES CAST AS A % OF ISSUED SHARE CAPITAL

VOTES WITHHELD

1

To receive the Company's Accounts and the Reports of the Directors and Auditor for the year ended 31 December 2015

 

924,514,473

99.61

3,665,459

0.39

928,179,932

73.40%

8,998,621

2

To confirm dividends

 

933,191,043

99.69

2,915,972

0.31

936,107,015

74.03%

1,071,537

3

To re-appoint KPMG LLP, London as Auditor

 

929,918,594

99.56

4,151,154

0.44

934,069,748

73.87%

3,108,804

4

To authorise the Directors to agree the remuneration of the Auditor

 

934,984,319

99.89

988,556

0.11

935,972,875

74.02%

1,204,865

5a

To re-elect Leif Johansson as a Director

 

861,678,834

94.69

48,321,545

5.31

910,000,379

71.96%

27,177,942

5b

To re-elect Pascal Soriot as a Director

 

935,167,473

99.93

697,471

0.07

935,864,944

74.01%

1,342,796

5c

To re-elect Marc Dunoyer as a Director

 

931,875,086

99.58

3,920,615

0.42

935,795,701

74.00%

1,380,982

5d

To re-elect Cori Bargmann as a Director

 

935,157,654

99.93

635,873

0.07

935,793,527

74.00%

1,384,110

5e

To re-elect Geneviève Berger as a Director

 

935,199,102

99.93

622,099

0.07

935,821,201

74.00%

1,356,436

5f

To re-elect Bruce Burlington as a Director

 

933,026,505

99.70

2,762,355

0.30

935,788,860

74.00%

1,389,088

5g

To re-elect Ann Cairns as a Director

 

933,220,149

99.72

2,618,183

0.28

935,838,332

74.01%

1,339,989

5h

To re-elect Graham Chipchase as a Director

 

919,686,570

98.97

9,526,012

1.03

929,212,582

73.48%

7,965,366

5i

To re-elect Jean-Philippe Courtois as a Director

 

933,177,891

99.72

2,593,420

0.28

935,771,311

74.00%

1,406,637

5j

To re-elect Rudy Markham as a Director

 

923,984,532

98.74

11,766,347

1.26

935,750,879

74.00%

1,427,442

5k

To re-elect Shriti Vadera as a Director

 

927,479,182

99.11

8,287,726

0.89

935,766,908

74.00%

1,410,552

5l

To re-elect Marcus Wallenberg as a Director

 

870,828,312

95.76

38,511,577

4.24

909,339,889

71.91%

27,837,158

6

To approve the Annual Report on Remuneration for the year ended 31 December 2015

836,396,151

89.61

96,959,428

10.39

933,355,579

73.81%

3,822,290

7

To authorise limited EU political donations

 

908,106,542

97.83

20,185,176

2.17

928,291,718

73.41%

8,886,009

8

To authorise the Directors to allot shares

 

849,809,843

90.97

84,303,774

9.03

934,113,617

73.87%

3,064,122

9

To authorise the Directors to disapply pre-emption rights

 

922,425,478

98.82

11,009,374

1.18

933,434,852

73.82%

3,742,888

10

To authorise the Company to purchase its own shares

 

926,166,577

98.96

9,722,078

1.04

935,888,655

74.01%

1,289,613

11

To reduce the notice period for general meetings

 

829,946,353

88.85

104,116,202

11.15

934,062,555

73.87%

3,115,081

 

 

 

Issued capital

As at 27 April 2016, the number of issued shares of the Company was 1,264,542,488 ordinary shares, which was the total number of shares entitling the holders to attend and vote for or against all the resolutions at the AGM. In accordance with the Company's Articles of Association, on a poll every member present in person or by proxy has one vote for every share held.

 

 

A C N Kemp

Company Secretary

29 April 2016

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
RAGPGUGACUPQGAB
Date   Source Headline
24th Feb 20236:15 pmRNSAstraZeneca prices a EUR1.5bn bond offering
24th Feb 20232:05 pmRNSAstraZeneca acquires CinCor for cardiorenal asset
24th Feb 202311:00 amRNSDirector/PDMR Shareholding
23rd Feb 20237:00 amRNSAstraZeneca enters agreement with KYM for CMG901
22nd Feb 20237:10 amRNSFiling of Form 20-F with SEC
21st Feb 202311:00 amRNSAnnual Financial Report
13th Feb 20232:01 pmRNSDirector/PDMR Shareholding
13th Feb 20232:00 pmRNSDirector/PDMR Shareholding
9th Feb 20237:00 amRNSFinal Results
1st Feb 20233:00 pmRNSTotal Voting Rights
26th Jan 20236:15 pmRNSUpdate on Evusheld US EUA
16th Jan 20237:00 amRNSAcquisition of Neogene Therapeutics completed
11th Jan 20231:00 pmRNSAirsupra (PT027) approved in US for asthma
9th Jan 20237:00 amRNSAstraZeneca acquire CinCor for cardiorenal asset
3rd Jan 20233:00 pmRNSTotal Voting Rights
30th Dec 202211:00 amRNSDirector/PDMR Shareholding
28th Dec 20227:05 amRNSCalquence Japan approval for treatment-naïve CLL
28th Dec 20227:00 amRNSImfinzi, Imjudo approved in Japan for 3 cancers
21st Dec 20227:05 amRNSLynparza approved in EU for prostate cancer
21st Dec 20227:00 amRNSImfinzi approved in EU for biliary tract cancer
19th Dec 20227:20 amRNSEnhertu recommended for EU approval in HER2-low BC
19th Dec 20227:15 amRNSEnhertu approved in EU for gastric cancer
19th Dec 20227:10 amRNSImfinzi + Imjudo recommended for approvals in EU
19th Dec 20227:05 amRNSUpdate on Imfinzi PEARL trial
19th Dec 20227:00 amRNSForxiga CHMP opinion for symptomatic chronic HF
15th Dec 20227:00 amRNSUpdate on US review of Lynparza PROpel sNDA
8th Dec 20221:30 pmRNSCapivasertib PFS in HR-positive breast cancer
1st Dec 20223:00 pmRNSBlock listing Interim Review
1st Dec 20223:00 pmRNSTotal Voting Rights
30th Nov 20227:05 amRNSAstraZeneca announces sale of West Chester site
29th Nov 20227:00 amRNSAstraZeneca to acquire Neogene Therapeutics
23rd Nov 20223:30 pmRNSDirector/PDMR Shareholding
14th Nov 20227:10 amRNSEnhertu recommended for EU approval in gastric
14th Nov 20227:05 amRNSImfinzi recommended for approval in the EU for BTC
14th Nov 20227:00 amRNSLynparza combo recommended in the EU for mCRPC
11th Nov 20227:00 amRNSImfinzi + Imjudo approved in US for lung cancer
10th Nov 20227:00 amRNSYTD and Q3 2022 Results
9th Nov 20227:00 amRNSFDA Advisory Committee recommends PT027 in asthma
4th Nov 20227:00 amRNSBeyfortus (nirsevimab) approved in EU
1st Nov 20223:00 pmRNSTotal Voting Rights
26th Oct 20227:00 amRNSCapivasertib Phase III trial met primary endpoints
25th Oct 20227:00 amRNSUpdate on MESSINA Phase III trial
24th Oct 20227:00 amRNSImfinzi + Imjudo approved in advanced liver cancer
3rd Oct 20223:00 pmRNSTotal Voting Rights
30th Sep 202210:30 amRNSBoard Committee Changes
27th Sep 20227:05 amRNSKoselugo approved in Japan for NF1
27th Sep 20227:00 amRNSTezspire approved in Japan for severe asthma
23rd Sep 20227:00 amRNSUltomiris approved in EU for gMG
23rd Sep 20227:00 amRNSUltomiris approved in EU for gMG
22nd Sep 20227:00 amRNSLynparza approved in China for ovarian cancer

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.